Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.68 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.64 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.64 |
| ▸ | CCR3 | P51677 | 4/20 | 0.62 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.61 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23649319 | 0.89 | SLC6A2 (0.74) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL24075739 | 0.85 | SLC6A2 (0.70) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL3867284 | 0.82 | PRMT3 (0.66) | PRMT6CARM1CCR3PRMT3PRMT1 | |
| SCHEMBL27008249 | 0.81 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL27016196 | 0.80 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL4852114 | 0.80 | SLC6A2 (0.63) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 | |
| SCHEMBL5888792 | 0.80 | HTR7 (0.68) | SLC6A2SLC6A3PRMT6CARM1CCR3 | |
| SCHEMBL24076758 | 0.79 | SLC6A2 (0.69) | SLC6A2SLC6A3SLC6A4CCR3 | |
| SCHEMBL18568473 | 0.79 | SLC6A2 (0.72) | SLC6A2SLC6A3SLC6A4CCR3 | |
| SCHEMBL313395 | 0.79 | MEN1 (0.65) | SLC6A2SLC6A3SLC6A4PRMT6CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | SLC6A2 883/4885SLC6A3 1207/4885SLC6A4 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.